Dr. Riess' clinical interests include lung cancer and other thoracic cancers (mesothelioma and thymoma) as well as head and neck cancers.
2279 45th Street
Sacramento, CA 95817
Department Referral Phone: 916-734-5959
M.S., Epidemioloyg and Clinical Research, Stanford University, Stanford CA, 2013
B.A., Swarthmore College, Swarthmore, PA, 2000
Oncology, Stanford University School of Medicine, Stanford, CA, 2013
American Board of Internal Medicine,
American Board of Medical Oncology,
American Society of Clinical Oncology
California Cancer Consortium
International Association for the Study of Lung Cancer
Southwest Oncology Group
Select Honors and Awards:
Paul Calabresi Career Development Award in Clinical Oncology, National Institute of Health, National Cancer Institute,
Stanford Cancer Institute Developmental Cancer Research Award, 2012
Ruth L. Kirschstein Clinical Research Scholar Award, National Institute of Health, National Cancer Institute, 2011
Stanford Translational and Applied Medicine Pilot Grant Award, 2011
Stanley S. Bergen Medal of Excellence, 2006
Stuart F. Alexander, MD Memorial Scholarship, 2006
J.T. Tai Foundation Scholarship, 2005
Muriel Genfan Memorial Scholarship, 2004
Select Recent Publications:
Riess, JW, Nagpal, S. EGFR Mutation Status and Brain Metastases in Non-Small Cell Lung Cancer: An Understudied Problem. Transl Cancer Res 2013;2(1):54-56.
Riess, JW, Nagpal, S. Das, M., Das, M. Neal, JW, Kim, JW, Wakelee, HA. A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. J of Thoracic Oncology 2013 Feb;8(2):e17-8.
Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012 Mar;30(3):231-5.
Riess, JW, Wakelee, HA. Metastatic Non-Small Cell Lung Cancer Management: Novel Targets and Recent Clinical Advances. Clin Adv Hematol Oncol. 2012 Apr;10(4):226-34.
Das M*, Riess JW*, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer. 2012 May:77:421-26. * Co-first authors who contributed equally.
Naqpal, S. Riess, J. Wakelee, H. Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge. Current Treatment Options in Oncology 2012 July:13;491-504.
Riess, JW, Neal, JW. Targeting Fibroblast Growth Factor Receptor and Discoidin Domain Receptor 2 in Non-Small Cell Lung Cancer (NSCLC). J of Thoracic Oncology. 2012 Dec. 7(16 Suppl 5):S385-6.
Riess, JW, Neal, JW. Targeting FGFR, Ephrins, Mer, MET, and PDGFR-α in Non-small Cell Lung Cancer. J of Thoracic Oncology 2011. Nov;6(11 Suppl 4):S1797-8.
Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nature Medicine 2002 Jul;8(7):681-6.